



August 29, 2023

Nevada Medicaid Web Announcement 3154

COVID-19 UNWIND: Emergency Use Authorization Revoked for Monoclonal Antibody and Injection Procedure Codes

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) revocation for the monoclonal antibody procedure codes listed below. The following antibody and injection procedure codes are not authorized effective with dates of service on or after the dates indicated below, and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA.

Procedure Code	Description	Effective End Dates
Q0222	Bebtelovimab, 175 mg	November 30, 2022
M0222	Bebtelovimab injection	
M0223	Bebtelovimab injection, home	
Q0220	Tixagev and Cilgav, 300 mg	January 26, 2023
Q0221	Tixagev and Cilgav, 600mg	
M0220	Tixagev and Cilgav, Inj	
M0221	Tixagev and Cilgav, Inj HM	

The following provider types (PTs) are impacted:

Provider Type	Description
12	Hospital, Outpatient
20	Physician, M.D., Osteopath, D.O.
24	Advanced Practice Registered Nurse (APRN)
77	Physician's Assistant

Claims for the above procedure codes with dates of service on or after the dates indicated above that paid instead of denying with error code 3340 (Service not covered by Nevada Medicaid) may be reprocessed automatically to recoup the payments. A future remittance advice will report the results of any reprocessed claims.

When claims are reprocessed, please be aware that all system and clinical claim editor edits are applicable. As a result, there may be no additional payment, and other claim denials may be received. Providers have the right to appeal denied claims, including those denied upon reprocessing. Please refer to [Medicaid Services Manual Chapter 100](#) and the [Billing Manual](#) for information concerning the claim appeal process and time frames.